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Abstract 
Objective 
We aimed to enhance the performance of a supervised model for clinical named-entity             
recognition (NER) using medical terminologies. In order to evaluate our system in French,             
we built a corpus for 5 types of clinical entities. 
Methods 
We used a terminology-based system as baseline, built upon UMLS and SNOMED. Then,             
we evaluated a biGRU-CRF, and an hybrid system using the prediction of the             
terminology-based system as feature for the biGRU-CRF. ​In English, we evaluated the NER             
systems on the i2b2-2009 Medication Challenge for Drug name recognition, ​which contained            
8,573 entities for 268 documents​. In French, we built APcNER, a corpus of 147 documents               
annotated for 5 entities (drug name, sign or symptom, disease or disorder, diagnostic             
procedure or lab test and therapeutic procedure). We evaluated each NER systems using             
exact and partial match definition of F-measure for NER. 
Results 
The APcNER contains 4,837 entities which took 28 hours to annotate, the inter-annotator             
agreement was acceptable for Drug name in exact match (85%) and acceptable for other              
entity types in non-exact match (>70%). For drug name recognition on both i2b2-2009 and              
APcNER, the biGRU-CRF performed better that the terminology-based system, with an           
exact-match F-measure of 91.1% versus 73% and 81.9% versus 75% respectively.           
Moreover, the hybrid system outperformed the biGRU-CRF, with an exact-match F-measure           
of 92.2% versus 91.1% (i2b2-2009) and 88.4% versus 81.9% (APcNER). On APcNER            
corpus, the micro-average F-measure of the hybrid system on the 5 entities was 69.5% in               
exact match, and 84.1% in non-exact match. 
Conclusion 
APcNER is a French corpus for clinical-NER of five type of entities which covers a large                
variety of document types. Extending supervised model with terminology allowed for an easy             
performance gain, especially in low regimes of entities, and established near state of the art               
results on the i2b2-2009 corpus. 
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Highlights 
● For 28 hours of annotation time, we built APcNER, a French corpus for clinical 
named-entity recognition which covers a large variety of document types 
● APcNER allowed to achieve an average 84% non-exact F-measure on five type of 
clinical entities 
● We provide consistent results on English and French corpora that give insight into the 
complementarity of a terminology with a supervised model 
Introduction 
Within the range of data covered by electronic health records (EHRs), clinical documents (e.              
g. discharge summaries or physicians' letters) are rich sources of information for various             
applications such as patient recruitment for clinical research, epidemiological surveillance,          
medical coding and decision-making tools ​[1]​. Information extraction tools must be tailored            
for application in the medical domain, where the language is both unstructured (e. g. free               
text) and semi-structured (e. g. drug lists), with a wide vocabulary.  
Named-entity recognition (NER) is the mention detection and type classification of named            
entities, where named entities are concepts that can be referenced by various linguistic             
expressions. In recent decades, there has been a growing interest in clinical-NER, the task              
of NER for medical concepts such as drug name, disease or signs ​[2]​. Supervised systems               
based on machine learning have proven to be more efficient than rule-based and             
terminology-based systems for NER​[3]​. Research efforts have then been made to unify            
these methods in hybrid systems, in a purely unsupervised ​[4,5] or semi-supervised fashion             
[6–8]​. Such approaches are motivated by the necessity to reduce the need for manually              
annotated examples in the case of a supervised system, or the need for handwritten rules by                
experts in the field of rule-based and ontological systems. 
In addition, for languages other than English, annotated corpora and ontologies are scarcer.             
For instance, in French, there is only one annotated clinical corpus which covers a small               
subset of the medical domain ​[9]​, and international ontologies such as the ​Unified Medical              
Language System (​UMLS​®) are not fully translated ​[10]​. The development cost of such             
annotated corpus is very high, as it has been reported that annotating 5 medical documents               
for 12 entities take on average 82 mins ​[9]​. 
In this study, we aimed to evaluate a clinical-NER system which development could scale up               
to the different uses of a large French data warehouse ​[11]​. First, we built an annotated                
corpus for five clinical entity types and present the details of the annotation process. Second,               
we evaluated three different systems: 1/ a terminology-based system built upon ​the            
Unstructured Information Management Architecture (apache-UIMA​®​) framework, 2/ a        
supervised neural model based on a biGRU-CR​F architecture, and 3/ an hybrid system.             
These experiments were achieved on our French corpus as well as on a well-known, freely               
available corpus in English, for comparison purposes. 
 
Methods 
Corpus and annotation process 
We used two corpora in this study, an English corpus from the i2b2-2009 Medication              
challenge (i2b2-2009) ​[12] and a French corpus APcNER, with clinical reports extracted from             
the AP-HP data warehouse ​[11]​. 
 
i2b2-2009 corpus 
The original corpus included 1243 de-identified discharge summaries, 17 of which were            
annotated by the i2b2 team, and 251 collectively annotated by the challenge participants.             1
Overall, the 268 annotated documents of the corpus contained 337,745 tokens, 8,573            
entities and 17,933 sentences, for a vocabulary of 23,214 tokens. The median sentence             
length was 13. The overall 8,573 entities, comprised 6,488 (75%) unigrams, 1,053 (12%)             
bigrams and 1,029 (12%) longer mentions. These 268 discharge summaries were randomly            
assigned to a train (70%), development (15%) and test set (15%). We only kept the name of                 
the drug from the annotations and discarded the dose and other drug-related information.  
We also used a randomly sampled subset of the i2b2-2009 train set, to include the same                
number of drug name entities than the APcNER corpus, for quantitative comparison            
purposes. We call this smaller corpus “i2b2-small”.  
 
 
APcNER corpus 
We randomly sampled (stratified on document types) 147 documents from the dataset used             
for de-identification at AP-HP, excluding prescriptions and admission reports. The AP-HP           
de-identification dataset is a set of 3223 French-language medical documents sampled -            
with upsampling of rare documents types - over 50 millions documents from the AP-HP Data               
Warehouse, which included EHR data from 39 hospitals. The APcNER included 4 main             
types of documents: discharge summaries, letters from physicians, operating reports and           
additional examination reports. Detailed document types can be found in the supplementary            
Table S1. We based our annotation guideline on the UMLS® semantic types ​[13]​, Table 1               
details the 5 medical entities that we annotated (drug name, sign or symptom, disease or               
disorder, diagnostic procedure or lab test and therapeutic procedure). We used BRAT Rapid             
Annotation Tool (BRAT) ​[14]​. The general guidance for annotation was to annotate the most              
complete entities (e. g. “Non-ST segment elevation myocardial infarction” and not only            
“myocardial infarction”) with no possible overlap between entities (see Appendix Section 2            
for the detailed annotation guideline). Documents were annotated by groups of 10 and the              
annotation time monitored. Documents were pre-annotated using a terminology-based         
annotator (see below). IL, a medical resident, annotated all the dataset. Then, in order to               
estimate the quality of the guidelines, we randomly selected 10 documents that NG, a              
1 ​Note that the original test set used during the i2b2 challenge is made of the 251 collectively 
annotated documents. 
medical doctor, annotated blindly. We then assessed the agreement between the two            
annotators. Conflicting annotations have been discussed between IL and NG and are            
referenced in the Annotation Guideline (see Appendix Section 2). IL went through all the              
documents a second time in order to disambiguate the conflicting annotations. Finally, for             
homogenization purposes, we fitted a simple conditional random field (CRF) model to the             
dataset with the default NER features using Wapiti ​[15]​. We used this model to detect               
annotation inconsistencies or case errors, and manually corrected them. Finally, we           
randomly divided all the documents into 6 folds by stratifying on the types of documents and                
the length of the documents. The corpus is made available on condition that a research               
project is submitted to the scientific and ethics committee of the AP-HP health data              
warehouse (​https://recherche.aphp.fr/eds/recherche/​). 
 
Clinical-NER systems 
For all experiments, we used the inside, outside, beginning (IOB) tagging scheme ​[16]​. For              
an entity of type DRUG, the first token of such entity is coded B-DRUG, if the entity is                  
constituted of multiples tokens, the following tokens are coded I-DRUG, and all tokens             
outside entities are coded O. For instance, “placed on heparin sodium” is encoded “O O               
B-DRUG I-DRUG”. 
 
 
Entity types Semantic Type UMLS Semantic  
Tree Number 
Number of terms  
(All sources) 
Drug name Antibiotic 
Clinical Drug 
Pharmacologic Substance 
Vitamin 
A1.4.1.1.1.1 
A1.3.3 
A1.4.1.1.1 
A1.4.1.1.3.4 
French: 24,932 
English: 96,547 
Sign or  
symptom 
Sign or Symptom A2.2.2 5,125 
Disease or  
disorder 
Mental or Behavioral Dysfunction 
Cell or Molecular Dysfunction 
Anatomical Abnormality 
Congenital Abnormality 
Acquired Abnormality 
Injury or Poisoning 
Pathologic Function 
Neoplastic Process 
Disease or Syndrome 
B2.2.1.2.1.1 
B2.2.1.2.2 
A1.2.2 
A1.2.2.1 
A1.2.2.2 
B2.3 
B2.2.1.2 
B2.2.1.2.1.2 
B2.2.1.2.1 
104,104 
Diagnostic 
procedure or  
lab test 
Laboratory or Test Result 
Laboratory Procedure 
Diagnostic Procedure 
A2.2.1 
B1.3.1.1 
B1.3.1.2 
16,974 
Therapeutic 
procedure 
Therapeutic or Preventive Procedure B1.3.1.3 20,926 
 
Table 1. UMLS semantic types extracted for each entity 
Terminology based system 
In English, we extracted drug names using regular expressions from UMLS® (including            
SNOMED 3.5 CT®) to create a large dictionary of drug names. In French, we used 10                
terminologies, 8 of which were previously referenced in ​[10] (ATC, BPDM, CCAM, CIM-10,             
DRC, SNOMED, UMLS), and 2 terminologies held by AP-HP (GLIMS, QDOC). Table 1             
details the extracted UMLS semantic types by entity type. Terms were extracted using             
minimal regular expression rules, then tokenized using Stanford CoreNLP ​[17]​. We           
discarded common terms based on Wikipedia word count. The matching rules were based             
on the apache-UIMA framework, CoreNLP and dkPRO and allowed multiple word matching,            
stop words, accent normalization and case insensitive matching. The source code is            
available with the GLP-3 license 
(​https://github.com/EDS-APHP/uima-aphp/tree/master/uima-dict​). Resolution of conflicting    
(overlapping) entities was done by randomly picking one of the conflicting entities. 
Supervised system 
Sentence segmentation and tokenization were performed using Stanford CoreNLP ​[17]​.          
Numbers were normalized to a unique token. We learned a biGRU-CRF (Bidirectional -             
Gated Recurrent Unit - Conditional Random Field) ​[3]​, based on the NCRF++            
implementation ​[18]​. The model takes 2 types of inputs. First, word embeddings trained with              
the Skip-Gram model ​[19]​, 2 millions AP-HP documents for French (dimension 200), and 2              
millions MIMIC ​[20] clinical notes for English (dimension 100). Second, character           
embeddings, which are processed by 1-dimensional convolution (kernel size 3) with           
max-pooling. The global token representation is the concatenation of the word and character             
embeddings (see Figure 1). The sequence of token representation is then processed            
forward and backward by the biGRU, which outputs a emission probability score for each              
entity class. Finally, the CRF decodes the sequence of labels by associating the emission              
probability score with a transition probability score (see Figure 2). We used a dropout rate of                
0.5, an L2-norm on the model weights and early stopping to prevent overfitting. We used               
Bayesian optimization [21] to perform hyperparameter tuning of the architecture (number of            
layers, number of neurons, character embedding dimension), learning rate and L2-norm.           
Note that with 1 entity type, NER is a 3 class classification problem, and with ​k entity types it                   
is a ​k x 2 + 1 classification problem, e. g. with the 5 entities type of APcNER we have 11                     
class to predict. 
 
Figure 1.​ Word representation 
 
Figure 2.​ biGRU-CRF architecture 
Hybrid system 
We proposed a hybrid system in which a supervised model was associated with a              
terminology-based model. For each token, we added a feature representing the class            
predicted by the terminology-based system described above, which is then encoded as a             
categorical embedding of dimension 5. This embedding is then concatenated to the word             
embedding from the supervised system. This terminology based feature can take two values             
per entity types (e. g. B-Drug Name; I-Drug name), as well as one value for the “Outside”                 
class. We also added a context feature based on terminologies of sections headings that             
we developed internally. The French section headings terminology was created based on            
documents of the same distribution as the APcNER corpus, the English section heading             
terminology was created for the 2018 AP-HP Datathon based on MIMIC notes. For each              
token, the context feature was the class of the last section heading, following the order of the                 
document. Then, the context feature is encoded as a categorical embedding of dimension 5.              
This embedding is concatenated to the word embedding from the supervised system and the              
other feature embedding. 
 
Evaluation methodology and metrics 
First, we evaluated the systems on the i2b2-2009 corpus and its reduced version,             
i2b2-small, and on the APcNER corpus with labels limited to drug names. Then we              
evaluated the systems on the entire APcNER corpus, as one multi-class task. We compared              
the models based on F-measure, precision and recall using the CONLL definition: “​precision             
is the percentage of named entities found by the learning system that are correct. Recall is                
the percentage of named entities present in the corpus that are found by the system. A                
named entity is correct only if it is an exact match of the corresponding entity in the data file​”.                   
We also compared the model based on partial match, which allowed the boundaries of the               
entity to mismatch.  
Neural network models training is highly non-deterministic and is subject to the random seed              
choice. Because of this variability during the training phase, we performed five experiments             
for each model presented in this work, and reported the mean, minimum and maximum of               
each metric. 
For the i2b2-2009 corpus, we selected the optimal set of hyperparameters for the supervised              
model based on a development set, including the optimal epoch stop, and evaluated on the               
test set the models trained on the train+dev set. For ​APcNER​, we selected the optimal set of                 
hyperparameters for the supervised model by 6 fold cross-validation, we defined the optimal             
epoch stop as the mean of the optimal epoch stop for each fold. We evaluate the model on                  
each fold, after training it on the remaining 5 folds, using the same set of optimal                
hyperparameters. We then report the evaluation metrics computed over the 6 folds. 
  
Results 
Corpus and annotation process 
APcNER corpus 
The first round took in average 87 min per 10 documents and a total of 22 hours. The ​second                   
round took in average 28 min per 10 documents and a total of 7 hours. Both round took in                   
average 115 minutes per 10 documents and a total of 28 hours. The inter-annotator              
agreement after the first two round and before the CRF harmonization is reported in Table 2.                
For drug names, the inter-annotator agreement is acceptable (F-measure .85) and good            
considering non-exact match (F-measure .92). Overall, the 147 documents of the corpus            
contain 80,421 tokens, 4,837 entities and 3,093 sentences, for a vocabulary of 12,523             
tokens. The median sentence length is 14. 
 
Entity types Non exact 
F-measure 
Exact 
F-measure 
# entities n-grams (%) 
n = 1 n = 2 n ≥ 3 
Drug name .92 .85 1076 1014 (94) 54 (.5) 8 (.1) 
Sign or 
symptom 
.71 .55 432 356 (82) 65 (15) 11 (.3) 
Disease or 
disorder 
.77 .65 1672 1238 (74) 330 (20) 104 (.6) 
Diagnostic 
procedure or 
lab test 
.87 .70 1156 808 (70) 297 (27) 51 (.4) 
Therapeutic 
procedure 
.71 .51 501 414 (83) 73 (15) 14 (.3) 
 
Table 2. APcNER inter-annotator agreement. 
The F-measure is the harmonic mean between precision and recall computed as in Conll 2003.               
Inter-annotator agreement is evaluated on a random subset of APcNER of 10 documents. 
  
Clinical-NER systems 
  Exact-match Partial-match 
Corpus System F​a 
[min-max] 
P​b 
[min-max] 
R​c 
[min-max] 
F​a 
[min-max] 
P​b 
[min-max] 
R​c 
[min-max] 
i2b2-2009 Terminologies 73.0  76.7  69.7  84.6 88.9 80.6 
 biGRU-CRF 91.1 
[90.0-91.8] 
90.6 
[89.7-92.6] 
91.7 
[87.6-93.1] 
93.5 
[92.4-94.1] 
92.9 
[92.2-95.0] 
94.2 
[90.0-96.0] 
 Hybrid system 92.2 
[91.2-93.0] 
92.1 
[91.4-93.1] 
92.2 
[90.5-93.8] 
94.7 
[94.3-95.2] 
94.6 
[94.0-95.2] 
94.7 
[93.5-96.1] 
i2b2-small biGRU-CRF 85.6 
[84.7-86.2] 
85.2 
[83.0-87.2] 
86.0 
[84.2-89.6] 
90.4 
[89.7-91.2] 
90.1 
[87.2-92.0] 
90.8 
[88.6-94.1] 
 Hybrid system 87.8 
[85.9-88.8] 
88.2 
[86.8-89.4] 
87.4 
[83.7-89.7] 
90.6 
[85.1-93.0] 
92.0 
[90.8-93.4] 
89.4 
[80.1-93.8] 
APcNER Terminologies 75.0 70.8 79.7 77.7 73.3 82.5 
 biGRU-CRF 81.9 
[81.2-82.4] 
86.6 
[84.9-88.7] 
77.8 
[76.6-78.9] 
86.4 
[85.1-87.7] 
91.4 
[90.3-93.4] 
82.0 
[80.1-84.0] 
 Hybrid system 86.4 
[86.2-86.8] 
89.6 
[87.7-90.9] 
83.4 
[82.3-84.7] 
90.4 
[89.9-91.1] 
93.8 
[91.9-94.9] 
87.2 
[85.9-88.6] 
a​F-measure; ​b​Precision; ​c​Recall 
 
Table 3. Drug name recognition. 
Comparison between a terminology-based system, a supervised model (biGRU-CRF) and a hybrid            
system on the i2b2-2009 corpus, i2b2-small (a reduced version of the former corpus), and APcNER.               
The evaluation metrics are F-measure, precision and recall for exact match and partial match. 
 
Table 3 summarizes the results of Drug name recognition in the i2b2-2009 corpus,             
i2b2-small (reduced version of the former dataset) and the APcNER corpus. For both             
i2b2-2009 and APcNER, the biGRU-CRF outperforms the terminology-based system, with          
an exact-match F-measure of 91.1% versus 73% and 81.9% versus 75% respectively. For             
both i2b2-2009 and APcNER, the hybrid system outperforms the biGRU-CRF, with an            
exact-match F-measure of 92.2% versus 91.1% and 88.4% versus 81.9% respectively. The            
performance on i2b2-small is very close to the performance on APcNER for the hybrid              
system (with an exact-match F-measure of 87.8% and 86.4%). 
Table 4 summarises the results of clinical-NER on all the entity types of the APcNER corpus.                
For all three systems, the exact-match performance for Sign or symptom, Disease or             
disorder, Diagnostic procedure or lab test, Therapeutic procedure are much lower compared            
to Drug name. The difference between the biGRU-CRF and the terminologies are also more              
important than for Drug names, with exact-match F-measures of 55.2% versus 15.7% (Sign             
or symptom), 59.5% versus 30.9% (Disease or disorder), 75.9% versus 30.4% (Diagnostic            
procedure or lab test) and 61.3% versus 16.6% (Therapeutic procedure). The difference            
between exact-match and partial match metrics is also greater than for Drug names. The              
hybrid system outperforms the other systems for all entity types except Therapeutic            
procedure. Table S3 summarizes the hyperparameters of the models. 
 
 
  Exact-match Partial-match 
Corpus System F​a 
[min-max] 
P​b 
[min-max] 
R​c 
[min-max] 
F​a 
[min-max] 
P​b 
[min-max] 
R​c 
[min-max] 
All types 
(micro-average) 
Terminologies 32.5 49.2 24.3 48.4 73.5 36.1 
biGRU-CRF 67.1 
[66.8-67.6] 
69.1 
[68.3-69.4] 
65.2 
[64.4-66.1] 
82.9 
[82.8-83.2] 
85.0 
[84.4-86.0] 
80.9 
[80.7-81.3] 
Hybrid system 69.5 
[69.1-69.7] 
71.6 
[71.1-72.2] 
67.5 
[67.2-68.2] 
84.1 
[84.0-84.3] 
86.3 
[85.8-86.8] 
82.1 
[81.4-82.6] 
Drug name 
 
Terminologies 75.0 70.8 79.7 77.7 73.3 82.5 
biGRU-CRF 81.5 
[80.2-82.7] 
84.6 
[81.9-87.9] 
78.6 
[78.1-79.8] 
85.9 
[85.1-86.8] 
89.2 
[87.2-92.3] 
82.8 
[82.0-83.9] 
Hybrid system 85.9 
[85.2-86.7] 
87.3 
[86.7-88.6] 
84.5 
[83.4-85.4] 
90.4 
[89.9-91.0] 
92.0 
[90.6-92.7] 
89.0 
[87.9-89.6] 
Sign or 
symptom 
 
Terminologies 15.7 38.9 9.8 28.4 70.4 17.8 
biGRU-CRF 55.2 
[53.5-56.3] 
56.6 
[55.4-57.6] 
53.8 
[51.1-56.2] 
76.5 
[75.4-77.2] 
77.4 
[76.6-78.6] 
75.6 
[74.1-77.8] 
Hybrid system 59.9 
[59.6-60.1] 
61.6 
[59.8-63.3] 
58.3 
[57.2-59.3] 
78.8 
[78.2-79.4] 
80.3 
[78.7-82.3] 
77.4 
[75.8-79.4] 
Disease or 
disorder 
 
Terminologies 30.9 33.3 28.9 62.5 68.1 57.8 
biGRU-CRF 59.5 
[58.4-60.9] 
61.9 
[60.3-63.5] 
57.4 
[56.6-58.6] 
79.4 
[78.8-79.8] 
82.2 
[81.3-82.9] 
76.9 
[76.4-77.9] 
Hybrid system 62.4 
[61.2-63.0] 
64.5 
[63.1-65.1] 
60.4 
[59.3-61.0] 
80.9 
[80.6-81.1] 
83.1 
[82.9-83.4] 
78.8 
[78.0-79.2] 
Diagnostic 
procedure or lab 
test 
Terminologies 30.4 61.4 20.2 40.1 81.3 26.6 
biGRU-CRF 75.9 
[75.3-76.5] 
77.1 
[76.3-78.1] 
74.8 
[74.2-75.7] 
88.0 
[87.4-88.4] 
89.2 
[88.3-89.8] 
86.9 
[86.3-87.3] 
Hybrid system 77.7 
[77.5-77.8] 
79.0 
[78.5-79.4] 
76.4 
[75.8-76.6] 
88.5 
[88.4-88.7] 
89.8 
[89.5-90.1] 
87.3 
[87.1-87.9] 
Therapeutic 
procedure 
 
Terminologies 16.6 36.1 10.8 35.1 76.6 22.8 
biGRU-CRF 61.3 
[60.9-61.8] 
64.4 
[63.2-65.9] 
58.5 
[57.5-59.4] 
80.9 
[80.6-81.4] 
84.6 
[83.2-86.3] 
77.5 
[76.0-78.4] 
Hybrid system 60.2 
[59.7-60.9] 
64.4 
[63.4-66.3] 
56.5 
[55.2-58.0] 
80.1 
[79.4-80.6] 
85.1 
[83.6-87.6] 
75.7 
[73.6-77.2] 
a​F-measure; ​b​Precision; ​c​Recall 
 
Table 4. Multiclass clinical named entity recognition. 
Comparison between a terminology-based system, a supervised model (biGRU-CRF) and a hybrid            
system on the APcNER dataset. The evaluation metrics are F-measure, precision and recall for exact               
match and partial match. 
Discussion 
In this study, we built APcNER a corpus for clinical-NER of 5 types of entities (Drug names,                 
Sign or symptom, Disease or disorder, Diagnostic procedure or lab test, Therapeutic            
procedure). We then systematically evaluated a supervised model (biGRU-CRF) against a           
terminology-based system. Finally, we proposed to extend the supervised system by           
encoding the prediction of the terminology-based system as categorical embeddings. On the            
APcNER and on the i2b2-2009 corpora, the biGRU-CRF outperforms the terminology-based           
system, and the hybrid system is more efficient except for the Therapeutic procedure class. 
Both the biGRU-CRF and its extended version outperforms previous results from the i2b2             
2009 Medication Challenge (90% F-measure for the best team) ​[21]​. These results (mean             
92.2, range [91.2-93.0]) are very close to FABLE ​[22] which used ​bootstrapping​, a             
semi-supervised approach, leading to 93% F-measure. As the number of examples           
increases, the information brought by the terminology should become redundant with the            
one brought by the annotations, which could explain the relatively larger performance gain of              
the hybrid system in low regime of trained examples (see Table 3). Note that, as mentioned                
above, our test set is a sub-sample of the i2b2 test set used during the challenge. 
The difference in performance for the biGRU-CRF between the i2b2-2009 and the APcNER             
corpora is partially explained by their difference in number of annotated entities. Indeed, our              
results (see Table 3) on the reduced version of i2b2 show close performance with the hybrid                
system when the training set is reduced to the same number of entities than APcNER.               
Differences remain with the system using no external resources, but this can come from the               
fact that the domain covered by the APcNER corpus is much broader in terms of document                
types and medical specialities. Another noteworthy difference is that a drug name followed             
by its commercial name between brackets is annotated as a single entity in i2b2-2009, but               
as several separate entities in APcNER, which explains the difference in the distribution of              
long n-grams (n ≥ 3) between the two corpus (see Table 2). 
Another notable result is that the performance of the biGRU-CRF is much lower for other               
types of entities than Drug names, and the difference between exact match and partial              
match is larger (see Table 4). Along with the results of the APcNER annotation process               
(Table 2), it suggests that it is in part due to the longer size of entities. Indeed, compared to                   
Drug names, the other types of entities have between 3 and 6 times more entities composed                
of at least 2 tokens. The inter-annotator agreement is also lower for these types of entities,                
and the results of the biGRU-CRF are consistent with those of the the inter-annotator              
agreement. This is consistent with feedback from the annotation process that boundaries are             
more difficult to define for longer entities. In addition, the conflict between overlapping             
entities rarely concerns Drug names, whereas they are more likely to occur between             
Diagnostic and Therapeutic procedure (e. g. angiography), or between Disorder and Sign (e.             
g. hemiparesis). Following this analysis, we argue that for the APcNER corpus, the metric of               
reference should be the non-exact F-measure for entities other than Drug names. 
In comparison with MERLOT ​[9]​, which include 44,740 entities of 12 types, for 500              
documents from Hepato-gastro-enterology and Nutrition ward, APcNER is both smaller (147           
documents) and covering a larger domain (no restriction of medical specialty). The            
inter-annotator agreements for class common to both corpora are comparable, with Sign and             
Symptom exact F-measure 59% versus 55%, Drug names 90% versus 85%, and disorder             
77% versus 65% for MERLOT and APcNER, respectively.  
To our knowledge, our study is the first to provide, for a distribution of medical documents                
that is representative of that of an EHR (with the exception of imagery reports, prescriptions               
and initial observation), an estimation of the annotation cost for clinical-NER, which is             
achieving on average 84% non-exact match F-measure for 28 hours of annotations. Using             
active learning is likely to diminish this cost by 40 to 80% ​[23,24]​, hence achieving               
performance greater than 95% on this task seems reachable. In addition, we provide             
consistent results in English and French, which provide an insight into the complementarity             
of a terminology with a supervised model. 
The main limitation of our study is the small size of our corpus compared to the large domain                  
it covers. However, using cross-validation allowed us to maintain comparable regime in            
terms of numbers of entities with the test set of other corpus. If cross-validation is known to                 
present a risk of overfitting ​[25]​, we did not tuned the hyperparameters for the hybrid               
systems, hence the performance gain relative to the biGRU-CRF is a lower bound. Finally, in               
regards of the average low performance of the supervised model on APcNER (average             
F-measure of 67.1%), one could think the corpus unfit to allow for supervised learning.              
However, it still constitutes an important tool to evaluate semi-supervised or unsupervised            
systems. Combined with a more focused dataset (such as MERLOT), it could allow             
interesting transfer learning approaches to be tested. 
 
Conclusion 
APcNER is a French corpus for clinical named-entity recognition of five type of entities which               
covers a large variety of document types. Extending supervised model with terminology            
allows for an easy performance gain, especially in low regimes of entities. 
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